US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
US Judge Dismisses Gautam Adani Criminal Charges 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Gold Price Hits Two-Month High as Investors Await US Inflation Data 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
